Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

Dr. VICTOR NAVA – Pathology – Best Researcher Award

Published on by Oncology

Dr. VICTOR NAVA - Pathology - Best Researcher Award

GEORGE WASHINGTON UNIVERSITY - United States

AUTHOR PROFILE

Google Scholar
Orcid
Scopus

EARLY ACADEMIC PURSUITS

Victor Eduardo Nava began his academic journey at the Central University of Venezuela, where he pursued his Medical Degree from 1983 to 1990. This foundational education provided him with the essential knowledge and skills in medicine.After obtaining his M.D., Victor Eduardo Nava furthered his academic pursuits at Tulane University's Graduate School. Here, he earned a Master of Science degree from the Department of Parasitology in 1993.Continuing his academic journey, Nava pursued a Ph.D. at Johns Hopkins University's School of Public Health. Under the guidance of his advisor, J. Marie Hardwick, Ph.D., he specialized in Molecular Microbiology and Immunology, completing his doctoral studies in 1998.

PROFESSIONAL ENDEAVORS

Victor Eduardo Nava undertook his PGY1 Residency in Anatomic Pathology/Clinical Pathology at Georgetown University Hospital under the mentorship of Norio Azumi, M.D., Ph.D., in 2001-2002.From 2002 to 2004, Nava continued his residency in Anatomic Pathology at the National Institutes of Health/National Cancer Institute's Laboratory of Pathology. His mentors during this period were Elaine Jaffe, M.D., and Maria Merino, M.D. Nava completed a fellowship in Hematopathology at Georgetown University Hospital from 2004 to 2006, mentored by Metin Ozdemirli, M.D., Ph.D.

CONTRIBUTIONS AND RESEARCH FOCUS ON PATHOLOGY

Throughout his career, Victor Eduardo Nava has made significant contributions to the field of Pathology, particularly in Hematopathology and Surgical Pathology. His research has focused on molecular microbiology, immunology, and the pathology of hematological disorders.

IMPACT AND INFLUENCE

Dr. Nava's work has had a profound impact on the understanding and diagnosis of hematological diseases. His research and clinical expertise have influenced medical practices and contributed to advancements in the field of pathology.

ACADEMIC CITES

Victor Eduardo Nava has been recognized for his scholarly contributions with numerous citations in academic journals and publications. His research papers and studies have been referenced by peers and professionals in the field, highlighting the significance and relevance of his work.

LEGACY AND FUTURE CONTRIBUTIONS

As the Blood Bank Director and Attending Hematopathologist/Surgical Pathologist at the Veterans Affairs Medical Center in Washington, DC, and Assistant Professor at George Washington University since 2007, Dr. Nava continues to make a lasting impact. His dedication to teaching, research, and patient care ensures that his legacy will endure, with future contributions expected to further advance the field of Pathology.

NOTABLE PUBLICATIONS

Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing. 2024

Myelodysplastic Neoplasms (MDS): A Narrative Review from the Era of Precision Medicine. 2024

Novel Therapeutics for Malaria. 2023

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V<sup>2</sup>) Therapy. 2022

Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. 2022